AIM ImmunoTech CEO buys 5,900 shares at $0.219

AIM ImmunoTech’s CEO and President increased his direct AIM shareholdings through an open-market style purchase.

Rhea-AI Filing Summary

AIM ImmunoTech Inc. (AIM) reported that CEO and President Thomas K. Equels purchased 5,900 shares of its Common Stock on September 14, 2026, in a purchase characterized as an open market or private transaction at $0.219 per share. Following this transaction, he holds 69,822 shares with direct ownership, and no Rule 10b5-1 trading plan is reported.

Insider Trade Summary

Net Buyer: 5,900 shares

Net Buy 1 txn

Insider Equels Thomas K

Role CEO & President

Bought 5,900 shs ($1K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	5,900	$0.219	$1K

Holdings After Transaction: Common Stock — 69,822 shares (Direct)

Key Figures

Shares purchased: 5,900 shares Purchase price per share: $0.219 per share Shares owned after transaction: 69,822 shares +2 more

5 metrics

Shares purchased 5,900 shares Common Stock bought by Thomas K. Equels on September 14, 2026

Purchase price per share $0.219 per share Price paid for AIM Common Stock on September 14, 2026

Shares owned after transaction 69,822 shares Directly owned by Thomas K. Equels following the September 14, 2026 purchase

Net shares bought in filing 5,900 shares Net buy based on all transactions reported in this Form 4

Number of buy transactions 1 transaction Count of purchase transactions reported for September 14, 2026

Key Terms

purchase in open market or private transaction, direct ownership, Rule 10b5-1 trading plan

3 terms

purchase in open market or private transaction financial

"Transaction coded as a purchase in open market or private transaction"

direct ownership financial

"The filing shows the resulting position as direct ownership"

Rule 10b5-1 trading plan regulatory

"The Rule 10b5-1 checkbox is not affirmed for this transaction"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did AIM ImmunoTech Inc. (AIM) disclose in this Form 4?

AIM ImmunoTech disclosed that CEO and President Thomas K. Equels purchased 5,900 shares of AIM Common Stock on September 14, 2026, in a transaction described as a purchase in the open market or a private transaction at $0.219 per share.

How many AIM (AIM) shares does the CEO own after this reported transaction?

After the reported purchase, CEO and President Thomas K. Equels beneficially owns 69,822 shares of AIM ImmunoTech Common Stock. The filing characterizes this position as direct ownership following the September 14, 2026 transaction.

Was the AIM (AIM) insider trade made under a Rule 10b5-1 trading plan?

No. The Form 4 indicates that the Rule 10b5-1 checkbox is not affirmed, and there are no footnotes stating that the September 14, 2026 purchase was made pursuant to a Rule 10b5-1 trading plan.

What price did the AIM (AIM) CEO pay per share in the latest purchase?

For the September 14, 2026 transaction, CEO and President Thomas K. Equels paid $0.219 per share for 5,900 shares of AIM ImmunoTech Common Stock, with the price reported on a per-share basis.

Does the Form 4 for AIM (AIM) report any stock sales by the CEO?

No. The Form 4 reports only a purchase of 5,900 shares of Common Stock by CEO and President Thomas K. Equels on September 14, 2026, and shows no sales or other types of dispositions in this filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/15/2026 - 04:31 PM Accepted by SEC EDGAR 09/15/2026 - 04:30 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Equels Thomas K

(Last) (First) (Middle)

2117 SOUTHWEST HIGHWAY 484

(Street)

OCALA FLORIDA 34473

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
AIM ImmunoTech Inc. [ AIM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CEO & President

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/14/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/14/2026		P		5,900	A	$0.219	69,822	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Thomas K Equels	09/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)